10x Genomics, Inc. (TXG) Shareholders & Insider Trades
10x Genomics shareholders at a glance
The largest holder of 10x Genomics stock is Fidelity Management & Research Co. LLC, with 17.6 million shares (14.67% of the company), worth about $1.10 billion as of September 25, 2026. The 10 largest holders together own 68.4%.
In Q2 2026, 406 institutional holdings reports listed 133.0 million shares worth $5.05 billion, up 6.4% in shares from Q1 2026.
Insiders reported 43 transactions in the last two years: 21 sales worth $3.13 million and 1 purchase. The newest one on file is from April 14, 2026 (Saxonov Serge Wilson, Chief Executive Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through April 14, 2026.
10x Genomics, Inc.
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest 10x Genomics shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Fidelity Management & Research Co. LLC | 17.6 million | 14.67% | $1.1B |
| T. Rowe Price Associates, Inc. (IM) | 14.0 million | 11.68% | $877.0M |
| BlackRock Advisors LLC | 10.1 million | 8.38% | $629.0M |
| ARK Investment Management LLC | 10.0 million | 8.32% | $625.0M |
| Vanguard Portfolio Management LLC | 7.0 million | 5.81% | $436.0M |
| Quantinno Capital Management LP | 5.5 million | 4.55% | $342.0M |
| Vanguard Capital Management LLC | 5.1 million | 4.23% | $317.0M |
| T. Rowe Price International Ltd. | 4.5 million | 3.78% | $283.0M |
| Sumitomo Mitsui Trust Group, Inc. | 4.2 million | 3.49% | $262.0M |
| Amova Asset Management Americas, Inc. | 4.2 million | 3.49% | $262.0M |
As of September 25, 2026.
10x Genomics institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 406 | 133.0 million | $5.1B |
| Q1 2026 | 343 | 125.0 million | $2.7B |
| Q4 2025 | 337 | 124.0 million | $2.0B |
| Q3 2025 | 332 | 124.0 million | $1.4B |
| Q2 2025 | 307 | 124.0 million | $1.4B |
| Q1 2025 | 288 | 114.0 million | $997.0M |
| Q4 2024 | 287 | 105.0 million | $1.5B |
| Q3 2024 | 278 | 105.0 million | $2.4B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
10x Genomics insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Saxonov Serge Wilson | Apr 14, 2026 | Chief Executive Officer | Sale at price 24.56 per share. | $122,784 |
| Saxonov Serge Wilson | Mar 24, 2026 | Chief Executive Officer | Sale at price 19.13 - 19.52 per share. | $288,908 |
| Saxonov Serge Wilson | Mar 3, 2026 | Chief Executive Officer | Stock Gift at price 0.00 per share. | – |
| Saxonov Serge Wilson | Mar 2, 2026 | Chief Executive Officer | Sale at price 22.67 - 23.18 per share. | $367,097 |
| Saxonov Serge Wilson | Feb 26, 2026 | Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Hindson Benjamin J | Feb 26, 2026 | President | Stock Award(Grant) at price 0.00 per share. | – |
| Taich Adam | Feb 26, 2026 | Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Teichmann Sarah A. | Feb 25, 2026 | Director | Sale at price 19.41 per share. | $147,108 |
| Hindson Benjamin J | Feb 23, 2026 | President | Sale at price 18.58 per share. | $145,379 |
| Taich Adam | Feb 23, 2026 | Chief Financial Officer | Sale at price 18.58 per share. | $166,593 |
| Saxonov Serge Wilson | Feb 23, 2026 | Chief Executive Officer | Sale at price 18.58 per share. | $178,928 |
| Saxonov Serge Wilson | Jan 5, 2026 | Chief Executive Officer | Conversion of Exercise of derivative security at price 1.20 per share. | $60,000 |
Newest 12 of 43 insider transactions in the last two years.
Questions and answers
Who owns the most 10x Genomics stock?
Fidelity Management & Research Co. LLC, with 14.67% of the company (as of September 25, 2026). Next: T. Rowe Price Associates, Inc. (IM) (11.68%) and BlackRock Advisors LLC (8.38%).
How many institutions own 10x Genomics stock?
406 institutional holdings reports listed 10x Genomics shares in Q2 2026, 133.0 million shares in all worth $5.05 billion.
Are 10x Genomics insiders buying or selling the stock?
In the last two years insiders reported 21 sales and 1 purchase (43 transactions in all); the newest on file is from April 14, 2026.
